- RecruitingPHASE4
Asciminib Roll-over Study
This study is for people who have already been taking a medicine called asciminib (or similar drugs) in a Novartis study for a type of blood cancer called CML. It allows them to keep taking the medicine if their doctor thinks it's still helping them.
For: Chronic Myelogenous Leukemia · Leukemia, Myelogenous, Chronic, BCR-ABL PositiveUnited States · Argentina · Austria - Active not recruitingPHASE3
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
This study looks at a new medicine called asciminib for adults with a type of blood cancer called CML. Researchers want to see if it works better than other standard CML treatments. It's for people recently diagnosed who haven't had treatment yet.
For: Chronic Myeloid Leukemia (CML) Philadelphia Chromosome PositiveUnited States · Australia · Austria - Active not recruitingPHASE3
A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)
This study compared two oral medications, asciminib and nilotinib, for adults newly diagnosed with a type of blood cancer called Philadelphia chromosome-positive chronic myeloid leukemia (CML). It looked at how well people tolerated each drug.
For: Philadelphia Chromosome-Positive Chronic Myeloid LeukemiaUnited States · Argentina · Bulgaria - Ongoing, recruitingHuman Pharmacology (Phase I)- Bioequivalence Study
Comparative Bioavailability of Nilotinib 200 mg Hard Capsules: A Single-Dose, Open-Label, Randomized, Four-Sequence, Four-Treatment, Four-Period Crossover Pilot Study in Healthy Subjects.
For: Primary Philadelphia-chromosome positive leukemia cells from chronic myelogenous leukemia (CML)Portugal - Ongoing, recruitingTherapeutic exploratory (Phase II)
A phase 2, multi-center, open-label, randomized study of oral asciminib added to imatinib versus continued imatinib versus switch to nilotinib in patients with CML-CP who have been previously treated with imatinib and have not achieved deep molecular response
For: Chronic Myelogenous Leukemia in chronic phase (CML-CP) · previously treated with imatinib and have not achieved deep molecular responseFrance · Spain · Italy